ArticleBiotechnology and bioengineering2025
The P134Q Sucrose Phosphorylase: Subtle Changes in the Catalytic Properties Benefit the Production of 2-O-α-Glucosyl Glycerol.
Article in Biotechnology and bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Protein engineering of Bifidobacterium adolescentis sucrose phosphorylase (BaSucP) has previously identified the P134Q enzyme variant for site-selective glycosylation at the 2-OH of glycerol. Besides improvement in selectivity, the P134Q-BaSucP additionally involves enhanced affinity for glycerol as a biochemical property potentially important for the production of 2-O-α-glucosyl glycerol (2GG), a commercialized skincare ingredient for cosmetic applications. Here, we performed a detailed kinetic model-based evaluation of P134Q-BaSucP in initial-rate and full reaction time course analyses to obtain a mechanistic interpretation and a comprehensive assessment of the process improvements achievable by the P134Q variant compared to the native enzyme. We show that P134Q-BaSucP involves ∼50-fold lowered reactivity with phosphate compared to native enzyme. The effect likely arises from decreased conformational flexibility of the substrate binding pocket in the P134Q variant that may also serve to constrain the positioning of glycerol for glycosylation. Glycerol reactivity is decreased ∼1.3-fold in P134Q-BaSucP; yet because the hydrolytic reactivity is lowered even more (threefold), the transfer efficiency to glycerol of the variant is enhanced ∼twofold compared to the native enzyme. Product inhibition by 2GG is decreased ∼threefold in P134Q-BaSucP. These properties of P134Q-BaSucP combine into major benefits for 2GG synthesis in terms of productivity and product yield. Model-based window-of-operation analysis for 2GG production from sucrose and glycerol further reveals the significant potential for saving on the excess glycerol used in the process that results from replacing the wild-type BaSucP with the P134Q variant. Collectively, this study shows the important interplay of enzyme and reaction engineering in the optimization of glycoside production through biocatalytic transglycosylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.